These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7581160)

  • 1. Filgrastim post-chemotherapy mobilizes more CD34+ cells compared to its use during steady-state haemopoiesis.
    Perez-Oteyza J; Garcia-Laraña J; Ramos P; Zamora C; Lopez-Jimenez J; Roldan E; Odriozola J
    Bone Marrow Transplant; 1995 Aug; 16(2):324-5. PubMed ID: 7581160
    [No Abstract]   [Full Text] [Related]  

  • 2. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
    Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
    Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
    Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
    Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection.
    Remacha AF; Martino R; Sureda A; Sarda MP; Solá C; Tugues D; Amill B; Garcia J; Oliver A
    Bone Marrow Transplant; 1996 Feb; 17(2):163-8. PubMed ID: 8640161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
    Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
    Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF.
    Schiødt I; Knudsen LM; Jensen L; Nikolajsen K; Gaarsdal E; Johnsen HE
    Bone Marrow Transplant; 1998 Jun; 21(11):1167-9. PubMed ID: 9645584
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF.
    Höglund M; Smedmyr B; Simonsson B; Tötterman T; Bengtsson M
    Bone Marrow Transplant; 1996 Jul; 18(1):19-27. PubMed ID: 8831991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells.
    Pedrazzoli P; Gibelli N; Pavesi L; Preti P; Piolini M; Bertolini F; Robustelli della Cuna G
    Anticancer Res; 1996; 16(4A):1781-5. PubMed ID: 8712701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection and expansion of CD34+ cells.
    McNiece IK
    Nouv Rev Fr Hematol (1978); 1995; 37(6):375-6. PubMed ID: 8907634
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers.
    Huhn RD; Yurkow EJ; Tushinski R; Clarke L; Sturgill MG; Hoffman R; Sheay W; Cody R; Philipp C; Resta D; George M
    Exp Hematol; 1996 Jun; 24(7):839-47. PubMed ID: 8647235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim.
    To LB; Bashford J; Durrant S; MacMillan J; Schwarer AP; Prince HM; Gibson J; Lewis I; Swart B; Marty J; Rawling T; Ashman L; Charles S; Cohen B
    Bone Marrow Transplant; 2003 Mar; 31(5):371-8. PubMed ID: 12634728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors.
    Martínez C; Urbano-Ispizua A; Rozman M; Rovira M; Marín P; Montfort N; Carreras E; Montserrat E
    Bone Marrow Transplant; 1999 Jan; 23(1):15-9. PubMed ID: 10037045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of peripheral blood stem cells mobilized with granulocyte colony-stimulating factor with or without prior standard-dose chemotherapy in patients with malignancy.
    Kobayashi N; Kasai M; Masauzi N; Ogasawara M; Kiyama Y; Naohara T; Higa T; Hashino S; Tanaka J; Imamura M
    Jpn J Clin Oncol; 1995 Dec; 25(6):250-7. PubMed ID: 8523821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single dose of filgrastim (rhG-CSF) to predict mobilisation of haemopoietic progenitors in patients with haematological malignancies.
    Mijovic A; Mufti GJ
    Bone Marrow Transplant; 1995 May; 15(5):813-4. PubMed ID: 7545491
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose granulocyte colony-stimulating factor mobilizes a higher proportion of early CD34(+) CD33(-) hemopoietic progenitors in children receiving treatment for solid tumors.
    Ortín M; Mathew LG; Patel SR; Millar B; Pandya N; Treleaven J
    Haematologica; 2004 Jul; 89(7):881-2. PubMed ID: 15257951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.